The International Journal of Tuberculosis and Lung Disease

Working Alliance for TB Drug Development, Cape Town, South Africa, February 8th, 2000 [Declaration]
pp. 489-490(2)
Author: The Working Alliance for TB Drug Development

Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages [Unresolved issues]
pp. 491-495(5)
Authors: L. Heifets; M. Higgins; B. Simon

Patient and disease characteristics, and outcome of treatment defaulters from the Singapore TB control unit—a one-year retrospective survey
pp. 496-503(8)
Authors: C.B.E. Chee; I.C. Boudville; S.P. Chan; Y.K. Zee; Y.T. Wang

Twenty-five years of tuberculosis in a French university hospital: a laboratory perspective
pp. 504-512(9)
Authors: J. Robert; D. Trystram; C. Truffot-Pernot; E. Cambau; V. Jarlier; J. Grosset

Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in a developing country with high HIV prevalence
pp. 513-518(6)
Authors: D. Wilkinson; W. Newman; A. Reid; S.B. Squire; A.W. Sturm; C.F. Gilks

HIV testing among tuberculosis patients in the era of antiretroviral therapy: a population-based study in Brazil
pp. 519-527(9)
Authors: K. DeRiemer; E.C.C. Soares; S.M.O. Dias; S.C. Cavalcante

Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis
pp. 528-536(9)
Authors: M.L. Joloba; J.L. Johnson; A. Namale; A. Morrissey; A.E. Assegghai; R.D. Mugerwa; J.J. Ellner; K.D. Eisenach

Human immunodeficiency virus-related tuberculosis and primary drug resistance in Bangkok, Thailand
pp. 537-543(7)
Authors: J. Punnotok; N. Shaffer; T. Naiwatanakul; U. Pumprueg; P. Subhannachart; A. Ittiravivongs; C. Chuchotthaworn; P. Ponglertnapagorn; N. Chantharojwong; N.L. Young; K. Limpakarnjanarat; T.D. Mastro

Treatment monitoring and prevalence of drug resistance in tuberculosis patients in Tehran
pp. 544-549(6)
Authors: A.R. Bahrmand; A.A. Velayati; V.V. Bakayev

A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis
pp. 550-554(5)
Authors: M. Zwarenstein; J.H. Schoeman; C. Vundule; C.J. Lombard; M. Tatley

Effect of anti-tuberculosis treatment on the tuberculin interferon- response in tuberculin skin test (TST) positive health care workers and patients with tuberculosis
pp. 555-561(7)
Authors: R.L. Stuart; D. Olden; P.D.R. Johnson; A. Forbes; P.M. Bradley; J.S. Rothel; M.L. Grayson

Antibody response to culture filtrate antigens of Mycobacterium tuberculosis during and after treatment of tuberculosis patients
pp. 562-569(8)
Authors: M.S. Imaz; E. Zerbini

Efficacy of common antiseptics against mycobacteria
pp. 570-576(7)
Authors: T. Rikimaru; M. Kondo; S. Kondo; K. Oizumi

3UTR polymorphisms in the NRAMP1 gene are associated with susceptibility to tuberculosis in Koreans
pp. 577-580(4)
Authors: S. Ryu; Y.K. Park; G.H. Bai; S.J. Kim; S.N. Park; S. Kang

Time between sputum examination and treatment in patients with smear-negative pulmonary tuberculosis
pp. 581-583(3)
Authors: F.M.L. Salaniponi; F. Gausi; J.H. Kwanjana; A.D. Harries

DNA fingerprinting of a national sample of Mycobacterium tuberculosis isolates, Botswana, 1995–1996
pp. 584-587(4)
Authors: S. Lockman; J.D. Sheppard; M. Mwasekaga; T.A. Kenyon; N.J. Binkin; C.R. Braden; C.L. Woodley; D.W. Rumisha; J.W. Tappero

Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain
pp. 588-591(4)
Authors: M. Casal; P. Ruiz; A. Herreras; Spanish Study Group of M. tuberculosis resistance Spain